Since 1 April 2026, biosimilar substitution is no longer a simple price comparison. Every dispensing decision starts with an unambiguous prescription and ends only when the pharmaceutical decision is traceable. For pre-filled syringes, pens, cartridges and vials, pharmacies must assess the product, route of administration, strength, pack and container as one connected data set.
The prescription must support a safe product assignment
An incomplete or contradictory prescription must not be converted into a free product choice. If information needed to identify the prescribed biological finished medicinal product is missing, the pharmacy should clarify it before dispensing. This particularly applies when only an active substance or a broad dosage form is stated and strength, pack size and container cannot be assigned reliably.
The first question is therefore not which item is cheapest. It is: Which specific starting product was prescribed, and is the prescription complete, plausible and technically executable?
Checks before any selection
- unambiguous active-substance and product reference,
- strength and prescribed quantity or pack size,
- dosage form and route of administration,
- container or application system, such as pre-filled pen, syringe or cartridge,
- any prescriber exclusion of substitution,
- identifiable pharmaceutical or patient-specific risks.
Substitutability requires a complete criteria match
The product to be dispensed must be authorised for at least one common indication and at least the same routes of administration. Strength and pack size must be identical. The dosage form must be the same or classified as interchangeable. Where the reported dosage form is the same, the container must also match.
A reference medicine and a biosimilar are therefore not freely interchangeable merely because the active-substance names look similar. The documented relationship to the same reference medicine and the complete technical and pharmaceutical match are decisive. Pharmacy software and current product directories must support this decision reliably.
The device is part of safe medicine use
One pen cannot automatically replace every other pen. Trigger mechanism, dose increments, viewing window, needle system, handling and training needs may differ. Even where formal criteria appear to be met, the container and application system must be assigned correctly.
When a product changes, the pharmacy should assess whether renewed instruction or counselling is needed. A technically possible substitution becomes safe in practice only when the patient can use the dispensed system correctly.
Contract rules do not replace pharmaceutical assessment
If an interchangeable contracted product is available, the contractual framework determines the economic selection. If no suitable contract exists or the intended item is unavailable, the pharmacy still does not gain unrestricted freedom. The applicable selection order, price ceiling and documentation requirements remain relevant.
Supply problems, urgent need or pharmaceutical concerns require the correct code and an individual, traceable explanation. Generic wording without a link to the actual case is not a robust safeguard against reimbursement disputes.
Patient-specific factors remain important
A prescriber may exclude substitution, removing the obligation to exchange. A pharmacy may also refrain from substitution after assessing individual factors such as known intolerance, allergy, previous problems with an application system or an unstable treatment situation. The decision should be professionally justified and auditable.
Substitution does not imply lower biosimilar quality. Authorisation and substitution rules are based on demonstrated comparability. Safe supply still requires review of the specific prescription and application situation.
A biosimilar SOP turns recurring questions into a stable process
Pharmacies should not leave the new dispensing logic to the memory of individual team members. A short, binding QMS process reduces queries, wrong decisions and reimbursement exposure.
- Validate the prescription: check completeness, plausibility and the specific starting item.
- Determine the substitution group: verify the reference relationship and current product data.
- Match the criteria: check indication, route, strength, pack, dosage form and container.
- Apply the selection path: consider contracts, availability, selection order and price ceiling.
- Assess patient risks: include device, ability to use it, intolerance and treatment stability.
- Document the decision: record clarification, special codes, pharmaceutical concerns and counselling.
Data quality determines speed and safety
Biosimilar dispensing requires current, consistent master data. Missing relationships between reference product and biosimilar, unclear container codes or outdated contract information create avoidable manual work. A useful data model connects product identifier, active substance, reference relationship, authorisation characteristics, device, pack, price, contract status and availability.
Pharmacy groups and wholesalers should monitor common stopping points: unclear prescriptions, missing device assignments, unavailable contracted products, clarification requests and documented concerns. These findings create concrete improvements for training, software and procurement.
tiger.PHARMA: making biosimilar dispensing operationally manageable
tiger.PHARMA combines pharmacy operations, pharmaceutical wholesale, QMS, product data and procurement processes. We develop SOPs and decision logic, structure product and substitution data, assess reimbursement and process risks and translate regulatory requirements into workable routines. Relevant services include pharmacy QMS, pharma data management and smart sourcing and pharmaceutical wholesale consulting.
Professional scope as at 17 August 2026. This article does not replace assessment of the specific prescription, the current contractual position or valid medicine data.